Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 13/20 | 0.97 |
| ▸ | P2RY6 | Q15077 | 14/20 | 0.71 |
| ▸ | P2RY4 | P51582 | 9/20 | 0.70 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.67 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3029457 | 1.00 | P2RY2 (0.97) | P2RY2P2RY6P2RY4PLA2G1BATG4B | |
| SCHEMBL31260663 | 0.86 | P2RY2 (0.78) | P2RY2P2RY6P2RY4 | |
| SCHEMBL31260661 | 0.86 | P2RY2 (0.78) | P2RY2P2RY6P2RY4 | |
| SCHEMBL31260665 | 0.85 | P2RY2 (0.77) | P2RY2P2RY6P2RY4 | |
| SCHEMBL12714933 | 0.84 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL26103138 | 0.84 | P2RY2 (0.75) | P2RY2P2RY6P2RY4 | |
| SCHEMBL21345250 | 0.84 | P2RY2 (0.75) | P2RY2P2RY6P2RY4 | |
| SCHEMBL31260676 | 0.84 | P2RY2 (0.75) | P2RY2P2RY6P2RY4 | |
| Cetyl Alcohol SCHEMBL9511379 | 0.84 | P2RY2 (0.70) | P2RY2P2RY6P2RY4 | |
| Dodecanol SCHEMBL9509966 | 0.84 | P2RY2 (0.70) | P2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618074-B2 | GPCR enhanced neuroprotection to treat brain injury | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-12-31 | — | — | US | claimed |
| US-20100216735-A1 | GPCR ENHANCED NEUROPROTECTION TO TREAT BRAIN INJURY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-08-26 | — | — | US | claimed |
| WO-2008113072-A2 | GPCR ENHANCED NEUROPROTECTION TO TREAT BRAIN INJURY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-09-18 | — | — | WO | claimed |
| EP-1011688-B1 | USE OF URIDINE 5'-DIPHOSPHATE AND ANALOGS THEREOF FOR THE TREATMENT OF LUNG DISEASES | UNIV NORTH CAROLINA (US) | 2005-02-02 | — | — | EP | claimed |
| US-6451288-B1 | USED IN METHODS OF HYDRATING LUNG MUCUS SECRETIONS AND TREATING LUNG DISORDERS SUCH AS CYSTIC FIBROSIS, VENTILATOR-ASSOCIATED PNEUMONIA, CHRONIC BRONCHITIS, CHRONIC OBSTRUCTIVE PULMONARY DISORDER AND PRIMARY CILIARY DYSKINESIA. | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2002-09-17 | — | — | US | claimed |
| US-6143279-A | HYDRATE LUNG MUSOUS SECRETIONS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2000-11-07 | — | — | US | claimed |
| US-20200261541-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| US-20180071367-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| EP-3268021-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION | Oxeia Biopharmaceuticals, Inc. (US) | 2018-01-17 | — | — | EP | disclosed |
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170266257-A1 | METHODS OF TREATING TRAUMATIC BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170121385-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| WO-2016144978-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20030125299-A1 | Method for treating or preventing inflammatory diseases | PETERSON WARD M (US) | 2003-07-03 | — | — | US | disclosed |
| US-6451288-B1 | USED IN METHODS OF HYDRATING LUNG MUCUS SECRETIONS AND TREATING LUNG DISORDERS SUCH AS CYSTIC FIBROSIS, VENTILATOR-ASSOCIATED PNEUMONIA, CHRONIC BRONCHITIS, CHRONIC OBSTRUCTIVE PULMONARY DISORDER AND PRIMARY CILIARY DYSKINESIA. | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2002-09-17 | — | — | US | disclosed |
| US-20020052336-A1 | Method of treating gastrointestinal tract disease with purinergic receptor agonists | INSPIRE PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6143279-A | HYDRATE LUNG MUSOUS SECRETIONS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2000-11-07 | — | — | US | disclosed |
| EP-1011688-A1 | USE OF URIDINE 5'-DIPHOSPHATE AND ANALOGS THEREOF FOR THE TREATMENT OF LUNG DISEASES | The University of North Carolina at Chapel Hill (US) | 2000-06-28 | — | — | EP | disclosed |
| US-6022527-A | HYDRATING LUNG MUCOUS SECRETIONS BY ADMINISTERING COMPOUNDS OF GIVEN FORMULA; TREATING CYSTIC FIBROSIS, CHRONIC BRONCHITIS, VENTILATOR ASSOCIATED PNEUMONIA AND OTHER LUNG DISEASES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2000-02-08 | — | — | US | disclosed |
| WO-1999009998-A1 | USE OF URIDINE 5'-DIPHOSPHATE AND ANALOGS THEREOF FOR THE TREATMENT OF LUNG DISEASES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266257-A1 | METHODS OF TREATING TRAUMATIC BRAIN INJURY | ATP6V1B2, FABP7, GHSR | P2RY2 2284/4885P2RY6 2398/4885P2RY4 2097/4885 |
| US-20100216735-A1 | GPCR ENHANCED NEUROPROTECTION TO TREAT BRAIN INJURY | P2RY1, P2RY2, P2RY11 | P2RY2 2/4885P2RY6 6/4885P2RY4 11/4885 |
| US-20200261541-A1 | METHODS OF TREATING MILD BRAIN INJURY | FABP7, PYGB, ATP6V1B2 | P2RY2 2738/4885P2RY6 3059/4885P2RY4 2618/4885 |
| US-20020052336-A1 | Method of treating gastrointestinal tract disease with purinergic receptor agonists | P2RY1, P2RY4, P2RX5 | P2RY2 4/4885P2RY6 8/4885P2RY4 2/4885 |
| US-20030125299-A1 | Method for treating or preventing inflammatory diseases | ADORA2B, ADORA2A, P2RY2 | P2RY2 3/4885P2RY6 23/4885P2RY4 20/4885 |
| US-20170121385-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | HTT, SNCA, NLN | P2RY2 1870/4885P2RY6 1951/4885P2RY4 1502/4885 |
| US-20180071367-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION | CRH, PYGB, CHAT | P2RY2 3181/4885P2RY6 2671/4885P2RY4 3498/4885 |
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | ATP6V1B2, GHSR, CRH | P2RY2 1512/4885P2RY6 1581/4885P2RY4 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.